The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis
- PMID: 29540583
- DOI: 10.1212/WNL.0000000000005279
The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis
Comment on
-
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.Neurology. 2018 Apr 10;90(15):e1324-e1332. doi: 10.1212/WNL.0000000000005292. Epub 2018 Mar 14. Neurology. 2018. PMID: 29540589 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical